Alzheimer's disease is not a single faulty switch. Amyloid-beta plaques, abnormal tau proteins, immune reactions, lipid handling, and changes to neuronal connections all interact. Research on brain enzymes offers several ways to probe these processes—but a biological target is not a cure. This article compares three independently sourced preclinical research programs.
1. IDOL: changing the balance of receptors and amyloid
A team led by Hande Karahan and Jungsu Kim at Indiana University School of Medicine examined an enzyme known as IDOL, which helps regulate receptors involved in lipid metabolism. In genetically engineered models of Alzheimer's-like disease, removing the Idol gene specifically from neurons reduced amyloid plaque burden. The team also reported changes in apolipoprotein E (APOE) and increased levels of receptors associated with APOE and lipid handling.
The mechanism is especially interesting because APOE biology links cholesterol transport and lipid regulation to Alzheimer's risk. The neuronal findings did not mean that deleting IDOL in people is safe, and the researchers said future work must test candidate inhibitors, safety, synaptic outcomes, and tau-related pathology. The underlying study appeared in Alzheimer's & Dementia in 2025; IU explained its implications in February 2026.
Read the original IDOL study → IU research explanation →
2. ACE in microglia: assisting the brain's cleanup cells
Microglia are resident immune cells that help respond to damage and clear debris from the brain. In a separate Cedars-Sinai study, researchers genetically boosted angiotensin-converting enzyme (ACE) in microglia of mice engineered to develop Alzheimer's-like amyloid pathology. Compared with their experimental controls, the animals had less plaque and neuronal damage and performed better on learning and memory tasks.
That result points to an intriguing strategy: strengthen selected cleanup functions of microglia instead of focusing only on the plaques themselves. But these were gene-engineered mice, not patients. Researchers must first establish whether human microglia behave similarly and whether a treatment can reproduce the useful effect without unacceptable risks.
Read the original Nature Aging study → Cedars-Sinai research explanation →
3. cPLA2: dialing down inflammation without disabling useful biology
A USC team studied calcium-dependent phospholipase A2 (cPLA2), an enzyme linked to inflammatory signaling in the brain. Its activity has been investigated in relation to APOE4, a major genetic risk factor for late-onset Alzheimer's. Researchers used computational screening and experimental testing to identify selective inhibitory compounds. In human brain-cell models and mouse experiments, a candidate inhibited pathological cPLA2 activity; animal experiments indicated that it could reach the brain and influence inflammatory pathways.
The difficulty is selectivity: cPLA2 also participates in normal cell function. Any future medication would need to suppress harmful activity without disrupting necessary signaling, and it would have to demonstrate meaningful benefit and acceptable safety in rigorous human testing.
USC's January 2026 report, with peer-reviewed research link →
Why these approaches matter together
These projects address different parts of the disease process. IDOL relates to neuronal receptors, APOE, and amyloid processing; ACE-enhanced microglia concern immune-cell cleanup; and cPLA2 inhibitors seek to alter damaging inflammation. It is plausible that future therapies might need to address more than one pathway, but combining these particular strategies is a hypothesis—not an established treatment plan.
What would count as a genuine breakthrough?
- Reproducibility: Independent laboratories reproduce the effects in different models.
- Safety: Targeting the enzyme does not impair essential brain, immune, vascular, or systemic functions.
- Human relevance: Relevant effects appear in patient-derived cells and, ultimately, in carefully conducted clinical trials.
- Patient benefit: Trials demonstrate slower cognitive or functional decline, not only lower plaque measurements or altered biomarkers.
- Duration and access: Long-term safety, affordability, and practical delivery are evaluated.
The MKP assessment
Promising research directions, not proven cures. Each study identifies a testable mechanism and a possible route to better treatments. None establishes that patients can benefit today by manipulating the named enzymes. Plaque reduction in a mouse and preserved cognition in a person are very different outcomes.
Discussion questions
How should researchers prioritize therapies that change plaques versus those that alter inflammation or preserve neurons? Which adverse effects would be especially important to monitor if an enzyme is active in multiple organ systems? What evidence should a science headline provide before using words such as “breakthrough” or “reversal”?
Sources & further reading
- Karahan, H., et al. (2025). Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors. Alzheimer's & Dementia. DOI: 10.1002/alz.70949.
- IU School of Medicine (February 12, 2026). Researchers identify promising Alzheimer's disease drug target.
- Gomez, A. R., et al. (2025). Boosting angiotensin-converting enzyme (ACE) in microglia protects against Alzheimer's disease in 5xFAD mice. Nature Aging.
- Cedars-Sinai (August 5, 2025). Preclinical study: Enzyme could help treat Alzheimer's disease.
- USC (January 20, 2026). Promising new target for Alzheimer's-linked brain inflammation (with journal link).
Editorial note: This evidence review was prompted by an October 14, 2026 Futura headline shared with MKP. The screenshot did not include the article body or a direct link, so MKP has not attributed any of these specific experiments to that headline. This article instead summarizes independently verified research. Research coverage is educational, not personal medical advice.